Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Murielle Roussel, Philippe Moreau, Benjamin Hébraud, Kamel Laribi, Arnaud Jaccard, Mamoun Dib, Borhane Slama, Véronique Dorvaux, Bruno Royer, Laurent Frenzel, Sonja Zweegman, Saskia K. Klein, Annemiek Broijl, Kon-Siong Jie, Jianping Wang, Véronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Katharine S. Gries, John Fastenau, Pieter Sonneveld